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4 Cannabinoid agonists suppress nociceptive transmission and inhibit pain-related behavior in animal models of acute and persistent nociception (for review, see (Hohmann, 2002) and (Malan et al., 2002) ). CB 1 and CB 2 receptor subtypes mediate cannabinoid antinociception.
Whereas CB 1 is expressed primarily in the central nervous system (Matsuda et al., 1990; Munro et al., 1993; Zimmer et al., 1999) , CB 2 is expressed primarily in cells of the immune system (Lynn and Herkenham, 1994) , and is absent in neurons of the central nervous system (Munro et al., 1993; Zimmer et al., 1999; Buckley et al., 2000) . Thus, CB 2 -selective agonists fail to elicit centrally-mediated cannabimimetic effects such as hypothermia, catalepsy and hypoactivity (Hanus et al., 1999; Malan et al., 2001) , and are unlikely to be psychoactive or addictive (for review see Malan et al., 2002) .
Both CB 1 (Hohmann and Herkenham, 1999b; a; Khasabova et al., 2002) and CB 2 (Ross et al., 2001 ); see also (Hohmann and Herkenham, 1999a; Price et al., 2003) ) have been identified in dorsal root ganglion cells, although it is unclear if CB 2 is expressed in primary afferent neurons.
Activation of CB 2 on nonneuronal cells in inflamed tissue is postulated to suppress the release of inflammatory mediators implicated in nociceptor sensitization (Mazzari et al., 1996) . However, the mechanism by which activation of CB 2 suppresses nociception remains poorly understood.
Intradermal administration of capsaicin induces hyperalgesia− an increase in pain behavior evoked by suprathreshold stimuli and/or a lowered threshold for pain (Gilchrist et al., 1996) . Primary hyperalgesia, observed at the site of injury, is characterized by sensitization to thermal and mechanical stimulation. Secondary hyperalgesia to mechanical stimulation is also observed in the surrounding uninjured tissue. Primary hyperalgesia, especially that elicited by noxious thermal stimulation, is mediated, in part, by sensitization of C-fiber mechanoheat (polymodal) nociceptors (Kenins, 1982; Konietzny and Hensel, 1983; Simone et al., 1987; Szolcsanyi et al., 1988; Baumann et al., 1991; LaMotte et al., 1992; Torebjork et al., 1992) . By contrast, secondary (mechanical) hyperalgesia involves central nervous system sensitization rather than sensitization of peripheral nociceptors (Baumann et al., 1991; LaMotte et al., 1992) .
Intradermal administration of vehicle fails to induce hyperalgesia or nocifensive behavior (Gilchrist et al., 1996) . Thus, intradermal capsaicin represents a useful tool for elucidating the neural mechanisms underlying CB 2 modulation of hyperalgesia.
The mixed CB 1 /CB 2 agonist WIN55,212-2, but not it's receptor-inactive enantiomer, suppresses capsaicin-evoked thermal and mechanical hyperalgesia and nocifensive behavior (Li et al., 1999) . Both spinal and peripheral mechanisms are implicated in cannabinoid modulation of capsaicin-evoked hyperalgesia. Intrathecal administration of WIN55,212-2 produces a CB 1 -mediated suppression of thermal and mechanical hyperalgesia but does not alter capsaicinevoked nocifensive behavior (Johanek et al., 2001) . Moreover, intraplantar pretreatment with WIN55,212-2 attenuates thermal hyperalgesia, but this effect is only partially reversed by the CB 1 antagonist SR141716A (Johanek et al., 2001) . Furthermore, this same treatment does not attenuate capsaicin-evoked mechanical hyperalgesia or the duration of nocifensive behavior (Johanek et al., 2001) . The inability of a CB 1 antagonist to block the suppression of nocifensive behavior and mechanical hyperalgesia by locally administered WIN55,212-2 implicate CB 1 -independent mechanisms in cannabinoid modulation of capsaicin-evoked hyperalgesia.
The recent development of selective agonists and antagonists for CB 2 has provided the pharmacological tools necessary to evaluate the role of CB 2 in modulating persistent nociception. CB 2 -selective agonists have recently been shown to induce antinociception in models of acute, inflammatory and nerve-injury induced nociception (Hanus et al., 1999; Clayton et al., 2002; Malan et al., 2002; Ibrahim et al., 2003; Nackley et al., 2003b; Quartilho et al., 2003) . AM1241 (Goutopoulos and Makriyannis, 2002) , a CB 2 -selective agonist (Fig. 1) , exhibits 340-fold selectivity for CB 2 over CB 1 (K i [CB 2 vs. CB 1 ] = 2 nM vs. 680 nM in mouse spleen vs. rat brain, respectively). AM1241, administered systemically or locally in the paw, attenuates thermal nociception and hyperalgesia (Malan et al., 2002; Quartilho et al., 2003) and suppresses carrageenan-evoked Fos protein expression and thermal and mechanical hyperalgesia (Nackley et al., 2003b) . AM1241 also attenuates neuropathic pain through a CB 2 mechanism that is not dependent upon CB 1 .
In the present work, we evaluated effects of AM1241, a selective CB 2 agonist, on behavioral sensitization evoked by intradermal administration of capsaicin (Gilchrist et al., 1996) and identified its site of action. To better understand neural mechanisms underlying antihyperalgesic actions induced by activation of CB 2 , we tested the hypothesis that AM1241 would suppress capsaicin-evoked primary thermal and mechanical hyperalgesia, tactile allodynia and nocifensive behavior through a CB 2 -specific mechanism. Pharmacological specificity was determined using competitive antagonists for CB 1 and CB 2 (SR141716A and SR144528, respectively). 
AM1241
Thermal hyperalgesia was evaluated using the radiant heat method (Hargreaves et al., 1988) . Rats were placed in plexiglass cages on an elevated glass platform. Subjects were acclimated to their environment for 15 -25 min prior to testing. Radiant heat was presented to the midplantar region of the hind paw through the floor of the glass platform. Stimulation was terminated upon paw withdrawal or after 25 s if the rat failed to withdraw from the stimulus.
After establishing stable baseline responsiveness to thermal stimuli, rats received intraperitoneal injections of AM1241 (33 or 330 µg/kg; n = 6 and n = 5 per group, respectively), SR144528 (1 mg/kg; n = 5), SR141716A (1 mg/kg; n = 5), SR144528 (1 mg/kg) coadministered with AM1241 
Rats were placed in plexiglass cages positioned over an elevated wire mesh platform and habituated to the testing environment for 15 -25 min prior to testing. Tactile allodynia was assessed using the up-down method (Chaplan et al., 1994) . Tactile allodynia refers to a nocifensive behavior elicited by a light touch or innocuous (here, mechanical) stimulus and was operationally defined as a lowering of the threshold for paw withdrawal from punctate mechanical stimulation. A series of nine calibrated filaments (with bending forces of 0. 35, 0.47, 0.67, 2.9, 4.2, 5.9, 9.0, 12.5, and 23.4 g; Stoelting) with approximately equal logarithmic spacing between stimuli (Mean ± SEM: 0.201 ± 0.06 and 0.199 ± 0.06 units in Experiment 2-3 and 5, respectively) were presented to each hind paw in successive order, whether ascending or descending. Filaments were positioned in contact with the hindpaw for a duration of 5 s or until a withdrawal response occurred. Testing was initiated with the middle filament of the series (4.2 g). In the absence of a paw withdrawal response, an incrementally stronger filament was presented and in the event of a paw withdrawal, an incrementally weaker filament was presented.
After the initial response threshold was crossed, this procedure was repeated four times in order to obtain a total of six responses in the immediate vicinity of the threshold. The pattern of withdrawals (X) and absence of withdrawal (O) was noted together with the terminal filament used in the series of six responses. The 50% g threshold was interpolated using the formula: 50% g threshold = (10 [Xf + kδ] )/10,000 where X f = value (in log units) of the final von Frey hair used; k = tabular value of pattern of positive (X) and negative (O) responses, as described by Chaplan et al. (1994) , and δ = mean difference (in log units) between stimuli. After establishing stable baseline responsiveness to punctate mechanical stimulation, rats received intraperitoneal injections of AM1241 (33 or 330 µg/kg; n = 6 per group, respectively),
SR144528
(1 mg/kg; n = 6), SR141716A (1 mg/kg; n = 6), SR144528 (1 mg/kg) coadministered with AM1241 (330 µg/kg; n = 6), SR141716A (1 mg/kg) coadministered with AM1241 (330 µg/kg; n = 6) or vehicle (n = 6) 20 min prior to capsaicin administration. Responsiveness to von
Frey monofilaments was reassessed at 5, 30 and 120 min post capsaicin.
Experiment 4: Assessment of nocifensive behavior following systemic administration of AM1241
Capsaicin-evoked nocifensive behavior was defined as guarding behavior that consisted of licking and failure to bear weight on the injected paw (Gilchrist et al., 1996) . Rats received intraperitoneal injections of AM1241 (33 or 330 µg/kg; n = 5 and 13 per group), SR144528 (1 mg/kg; n = 6), SR141716A (1 mg/kg; n = 6), SR144528 (1 mg/kg) coadministered with AM1241
(330 µg/kg; n = 6), SR141716A (1 mg/kg) coadministered with AM1241 (330 µg/kg; n = 6) or vehicle (n = 7) 20 min prior to capsaicin administration. The total time rats exhibited nocifensive behavior was measured over 5 min immediately following intradermal administration of capsaicin.
Experiment 5: Site of Action of AM1241
To address the site of action, AM1241 (33 µg/kg i.pl.; n = 6 per group per stimulus modality) or vehicle (n = 6 per group per stimulus modality) was administered locally in the ipsilateral paw just prior to intradermal administration of capsaicin. A separate group of rats received the same dose of AM1241 in the paw contralateral to the site of capsaicin injection (n = JPET #60079 11 6 per group per stimulus modality). Separate groups of rats were subsequently evaluated for thermal (at 10, 25, 40 and 55 min post capsaicin) and mechanical hyperalgesia and allodynia (at 10, 35 and 125 min post capsaicin) as described above.
Statistical Analysis
Behavioral data were analyzed parametrically using analysis of variance (ANOVA) for repeated measures (to assess thermal paw withdrawal latency and mechanical paw withdrawal frequency) and ANOVA (to assess nocifensive behavior). The Greenhouse-Geisser correction (Greenhouse and Geisser, 1959) was applied to all repeated factors to avoid spurious significance due to lack of homogeneity of variance and covariance in repeated factors. Mechanical thresholds within each group were analyzed by oneway nonparametric repeated measures ANOVA (the Friedman test). The nonparametric Kruskal-Wallis ANOVA by ranks was subsequently used to assess group differences in capsaicin-evoked paw withdrawal thresholds at time points characterized by maximal capsaicin-evoked allodynia. Post hoc comparisons following parametric and nonparametric ANOVA were performed using Fisher's protected least significant difference (PLSD) and Dunn's multiple comparison post hoc tests, respectively. P < 0.05 was considered to be statistically significant. 
RESULTS

AM1241
The threshold and frequency of paw withdrawal elicited by von Frey monofilaments did not differ between groups prior to intradermal administration of capsaicin ( Fig. 3 and 4 , respectively). Capsaicin lowered the threshold for paw withdrawal relative to baseline levels in rats receiving vehicle (Friedman statistic, Fr = 16.12, P < 0.002) or the low dose (Fr = 16.53, P < 0.001) of AM1241 ( Fig. 3A-B) . In vehicle-treated rats, the threshold for paw withdrawal was 71% and 59% lower, relative to baseline, at 5 (P < 0.05) and 30 (P < 0.05) min post capsaicin, respectively. In rats receiving the low dose of AM1241, paw withdrawal thresholds were 54%
lower, relative to baseline, at 5 min (P < 0.05) post capsaicin. By contrast, paw withdrawal thresholds were normalized to baseline levels and did not change over time following systemic administration of the high dose of AM1241 ( Fig. 3A-B) . At the time point of maximal alteration in paw withdrawal thresholds (5 min), the high dose of AM1241 suppressed capsaicin-evoked tactile allodynia (Kruskal-Wallis statistic, KW = 12.66, P < 0.002) relative to vehicle (P < 0.01) or the low (P < 0.05) dose of AM1241 (Fig. 3A) . Only the high dose of AM1241 increased paw withdrawal thresholds relative to vehicle at 30 (P < 0.01) min post capsaicin.
Capsaicin also lowered the threshold for paw withdrawal relative to baseline in groups receiving AM1241 (330 µg/kg i.p.) coadministered with SR144528 (Fr = 14.37, P < 0.003) or either SR144528 (Fr = 16.88, P < 0.0008) or SR141716A (Fr = 16.93, P < 0.0008) administered alone ( Fig. 3B ). Capsaicin-evoked allodynia was observed in each group at 5 (P < 0.01) and 30 min (P < 0.05) post capsaicin. By contrast, paw withdrawal thresholds were similar to baseline levels in groups receiving AM1241 either alone or together with SR141716A ( Fig. 3B) . At 5 min post capsaicin, the antiallodynic effect of AM1241 (KW = 23.09, P < 0.0004) was blocked by the CB 2 antagonist SR144528 (P < 0.05), but not by the CB 1 antagonist SR141716A (Fig. 3B ).
At 30 min post capsaicin, the AM1241-induced suppression of tactile allodynia (KW = 24.60, P < 0.0003) was similarly blocked by SR144528 (P < 0.05; Fig. 3B ). were similar to preinjection levels at all timepoints in groups receiving AM1241 (33 µg/kg i.pl.)
in the ipsilateral hind paw. Local administration of AM1241 (33 µg/kg i.pl.) reduced the frequency of capsaicin-evoked paw withdrawal to punctate mechanical stimulation from 90% to 50% at 10 min post capsaicin (Fig. 6B) ; this same dose induced less than a 10% reduction in mechanical hyperalgesia following systemic administration at 5 min post capsaicin (Fig. 4A) .
Capsaicin lowered the threshold for paw withdrawal in groups receiving vehicle in the capsaicin-treated paw (Fr = 15.32, P < 0.002) or AM1241 (33 µg/kg i.pl.) in the capsaicinuntreated paw (Fr = 16.20, P < 0.002) relative to baseline levels (Fig. 6C ). Allodynia was detected at 10 (P < 0.01 for each comparison) and 35 min (P < 0.05) post capsaicin in each condition. In vehicle-treated rats, capsaicin reduced paw withdrawal thresholds by 41% and 24%, relative to baseline, at 10 and 35 min post capsaicin, respectively. By contrast, mechanical thresholds did not differ from preinjection levels at any timepoint in groups receiving AM1241 (33 µg/kg i.pl.) locally in the capsaicin-injected paw. Local injections of AM1241 to the ipsilateral paw suppressed capsaicin-evoked allodynia at 10 (KW = 13.62, P < 0.002) and 35 min (KW = 11.21, P < 0.004) post capsaicin (Fig. 6C) . The median paw withdrawal threshold was higher in groups receiving AM1241 (33 µg/kg i.pl.) locally in the capsaicin-treated paw relative to groups receiving equivalent injections of vehicle (P < 0.05) at each time point. Paw withdrawal thresholds were also higher in groups receiving AM1241 locally in the capsaicintreated paw relative to the capsaicin-untreated contralateral paw at 10 (P < 0.001) and 35 min (P < 0.01) post capsaicin (Fig. 6C) . Suppressions of thermal and mechanical hyperalgesia and allodynia were absent when this same dose was applied locally in the paw contralateral to capsaicin administration (Fig. 6A-C) . Capsaicin-evoked pain behavior did not differ between groups receiving vehicle locally in the capsaicin-treated paw or AM1241 locally in the capsaicinuntreated paw in any study. Moreover, no group differences were detected in the capsaicinuntreated (contralateral) paw for any dependent measure.
DISCUSSION
In the present study, selective activation of cannabinoid CB 2 receptors attenuated the development of behavioral sensitization to thermal and mechanical stimulation in the capsaicin model of neurogenic inflammation. The CB 2 -selective agonist AM1241 induced a dosedependent suppression of capsaicin-evoked thermal and mechanical hyperalgesia and tactile allodynia. These actions were mediated by a peripheral mechanism because administration of AM1241 directly to the capsaicin-injected paw suppressed the development of thermal and mechanical hyperalgesia and allodynia whereas the same dose administered to the contralateral (capsaicin-untreated) paw was inactive. These data are in agreement with other studies showing that CB 2 -selective agonists are antinociceptive in models of acute and inflammatory nociception (Hanus et al., 1999; Clayton et al., 2002; Malan et al., 2002; Nackley et al., 2003b; Quartilho et al., 2003) . Our findings demonstrate that AM1241 suppresses capsaicin-evoked mechanical and thermal hyperalgesia, tactile allodynia and nocifensive behavior through a CB 2 -specific mechanism and extend recent observations made by Quartilho and colleagues (Quartilho et al., 2003) . This latter work showed that systemic administration of AM1241 induces a CB 2 -mediated suppression of thermal hyperalgesia (at 10 min post capsaicin) and flinching evoked by capsaicin administration to the dorsal hind paw surface (Quartilho et al., 2003) . Our data additionally demonstrate: 1) that local administration of AM1241 to the site of injury suppresses behavioral sensitization to capsaicin, consistent with a peripheral site of action, 2) that the suppressive effects of systemically and locally administered AM1241 generalize to multiple modalities of stimulation (mechanical as well as thermal), 3) that behavioral sensitization to each stimulus modality is completely blocked by the CB 2 antagonist SR144528 but not by the CB 1 antagonist SR141716A, and 4) reveal the time course of AM1241-induced suppressions of capsaicin-evoked thermal and mechanical hyperalgesia and tactile allodynia. The duration of capsaicinevoked mechanical hyperalgesia outlasts that of capsaicin-evoked thermal hyperalgesia (Gilchrist et al., 1996) . Our data show that the antihyperalgesic and antiallodynic effects of AM1241 (330 µg/kg i.p.) outlast the duration of capsaicin-evoked behavioral sensitization. More work is necessary to determine if AM1241 suppresses capsaicin-evoked plasma extravasation through activation of peripheral CB 2 receptors.
Intradermal administration of capsaicin to the plantar hind paw surface induced a single phase of nocifensive behavior consistent with other published reports (Gilchrist et al., 1996) .
Because nocifensive behavior terminated by 5 min post capsaicin, this behavior could not confound assessments of hyperalgesia or allodynia in the present work. AM1241 induced a dosedependent suppression of capsaicin-evoked nocifensive behavior. The AM1241-induced attenuation of nocifensive behavior was completely blocked by the CB 2 antagonist SR144528. In our study, a modest but significant blockade of the AM1241-induced suppression capsaicinevoked nocifensive behavior was also observed following coadministration with the CB 1 antagonist SR141716A. Thus, our data are also consistent with observations by Simone and colleagues that SR141716A only partially blocks the attenuation of capsaicin-evoked nocifensive behavior induced by the mixed CB 1 /CB 2 agonist WIN55,212-2 (Johanek et al., 2001 ).
The antihyperalgesic and antiallodynic actions of AM1241 were blocked by the CB 2 antagonist SR144528 but not by the CB 1 antagonist SR141716A. These findings are consistent with recent observations by our group demonstrating that pretreatment with AM1241 suppresses C-fiber-mediated responses and wind-up during the development of inflammation without reliably altering A-β or A-δ fiber-evoked responses; these electrophysiological effects were more pronounced in carrageenan-inflamed rats relative to noninflamed rats and were blocked selectively by the CB 2 antagonist SR144528 (Nackley et al., 2003a) . Intraplantar anandamide also attenuates noxious and nonnoxious mechanically-evoked responses in spinal wide dynamic range neurons in the presence of carrageenan inflammation, but not in its absence; these actions were blocked by the CB 2 antagonist SR144528 (Sokal et al., 2003) . The lack of efficacy of SR141716A in blocking the attenuation of capsaicin-evoked hyperalgesia induced by AM1241 is consistent with the absence of a neuronally expressed CB 2 receptor in the central nervous system (Munro et al., 1993; Zimmer et al., 1999; Buckley et al., 2000) . The functional significance of CB 2 mRNA expression in nonneuronal cells that coincides with the appearance of activated microglia following injury (Zhang et al., 2003) awaits further investigation.
A CB 2 mechanism does not tonically modulate nociceptive thresholds in the capsaicin model of persistent nociception. Neither SR144528 nor SR141716A, administered prior to intradermal capsaicin, altered nociceptive thresholds relative to vehicle. This observation is consistent with our failure to observe facilitation of carrageenan-evoked spinal Fos protein expression or pain behavior following preemptive systemic or intraplantar administration of SR144528 (Nackley et al., 2003b; Nackley et al., 2003c) . Moreover, systemic pretreatment with CB 1 and CB 2 antagonists, also failed to enhance Aβ-, Aδ-, and C-fiber-evoked responses and wind-up in spinal wide dynamic range neurons during the development of carrageenan inflammation (Nackley et al., 2003a) .
Intraplantar administration of the CB 2 agonist suppressed capsaicin-evoked hyperalgesia and allodynia relative to rats receiving an equivalent intraplantar injection of vehicle. Support for a local site of action for AM1241 in the present work is derived from the observation that AM1241 suppressed hyperalgesia and allodynia following local administration in the capsaicintreated paw but was inactive following local administration in the contralateral (capsaicin-untreated) paw. Pharmacological specificity of AM1241-induced actions was established using antagonists that were administered systemically, rather than locally in the paw. In the carrageenan model of inflammation, a local dose of AM1241 that is 121-fold higher than the local dose employed in the present study (4000 vs. 33 µg/kg i.pl.) was blocked selectively by a CB 2 but not by a CB 1 antagonist (Quartilho et al., 2003) . These findings suggest that the lower dose of AM1241 employed here is unlikely to be acting nonselectively at CB 1 .
Both the high dose of AM1241 (330 µg/kg i.p.) administered systemically and the low dose (33 µg/kg i.pl.) administered locally in the paw effectively normalized thermal and mechanical withdrawal thresholds to pre-capsaicin levels. For each route of drug administration, thermal paw withdrawal latencies and mechanical paw withdrawal thresholds were similar in rats receiving AM1241 (330 µg/kg i.p. or 33 µg/kg i.pl.) to baseline (pre-capsaicin) levels. Moreover, AM1241 (33 µg/kg i.pl.), administered locally in the paw, was more potent than the same dose administered systemically. These data are similarly consistent with a local site of action.
However, the local dose of AM1241was not sufficient to eliminate capsaicin-evoked mechanical hyperalgesia elicited by repetitive stimulation with von Frey monofilaments.
In the present study, capsaicin-evoked reductions in thermal paw withdrawal were similar in rats receiving a local injection of the DMSO vehicle to those observed in naive rats receiving the same concentration of capsaicin (51% in Fig. 6A vs. 50% decrease in latency reported by Gilchrist et al., 1996) . Moreover, in the present study, thermal and mechanical hyperalgesia and allodynia in the capsaicin-injected paw did not differ in groups receiving vehicle locally in the ipsilateral paw or AM1241 locally in the contralateral (capsaicin-untreated) paw. In addition, no group differences were detected in the contralateral hind paw in any dependent measure.
Importantly, intraplantar injections of the DMSO vehicle did not prevent detection of capsaicin-evoked hyperalgesia and allodynia or the antihyperalgesic and antiallodynic effects of locally administered AM1241 in the present study. Thus, possible alterations in sensory thresholds following injections of vehicle cannot account for the local antihyperalgesic and antiallodynic effects of AM1241observed here.
Our data indicate that selective activation of CB 2 with AM1241 is sufficient to suppress the activation of C-polymodal heat nociceptors that results in primary (thermal) hyperalgesia in the capsaicin model of persistent nociception. More work is necessary to determine if activation of CB 2 is sufficient to suppress the central nervous system sensitization that underlies secondary hyperalgesia to mechanical stimulation outside the zone of injection. Our data could parsimoniously be attributed, in part, to a direct effect of the CB 2 -selective agonist on primary afferent C-fibers. However, levels of CB 2 mRNA are similar to background in native dorsal root (Hohmann and Herkenham, 1999a) and trigeminal (Price et al., 2003) ganglia under conditions in which CB 1 mRNA was clearly demonstrated and CB 2 mRNA was highly expressed in rat spleen. Of course, different expression levels could be observed in acute or persistent pain states, or levels of CB 2 mRNA could be near the threshold for detection. CB 2 does not couple to calcium-Q or inward rectifying K + channels in CB 2 transfected cell lines (Felder et al., 1995) , suggesting that CB 2 mechanisms regulate neuronal excitability through other signal transduction systems (e.g. mitogen activated protein kinase; (Bouaboula et al., 1996) ) and/or modulation of nonneuronal cells (e.g. satellite glial cells).
The present work provides evidence that activation of a cannabinoid CB 2 mechanism in the periphery is sufficient to suppress thermal and mechanical hyperalgesia, tactile allodynia and nocifensive behavior evoked by intradermal capsaicin. Our data suggest that the failure of CB 1
antagonists to block mechanical hyperalgesia and nocifensive behavior following intraplantar administration of WIN55,212-2 (Johanek et al., 2001) 
